INTRODUCTION: Tuberculosis (TB) is one of the leading causes of morbidity and mortality with a global mortality rate at two million deaths per year while one third of the world's population is infected with the TB bacillus. OBJECTIVE: To determine the efficacy of the crude extracts of Erythrina abyssinica root bark on rifampicin-resistant TB. METHODS: Crude extracts of root bark of Erythrina abyssinica, were screened against three strains of Mycobacterium tuberculosis including rifampicin-resistant TMC-331. Susceptibility tests used the disc diffusion method and were done on solid Middle brook 7H10, while the Minimum Inhibitory concentration (MICs) and minimum bactericidal concentration (MBCs) were determined by the Microtitre plate method using Middle brook 7H9 broth. RESULTS: The total crude methanol extract showed activity against all the three strains of mycobacterium used, at 50mg/ml and diameters of zones of inhibition of up to 26 mm. Erythrina abyssinica total crude methanol extract showed the highest activity on the pan sensitive strain H37Rv (0.39±0.0 mg/ml) and the rifampicin resistant strain (TMC-331) (2.35±1.11 mg/ ml) and was also active on Mycobacterium avium (0.39±0.mg/ml. The values for isoniazid were 0.25µg/ml and 9.38µg/ml for H37Rv and TMC-331 respectively, while for rifampicin the MIC value was 0.25µg/ml for H37Rv but it was not active on TMC-331. Acute toxicity test gave an LD50 of 776.2mg/kg body weight while the phytochemical analysis showed the presence of alkaloids, tannins and flavones. CONCLUSION: The conclusion from the study was that Erythrina abbyssinica has antimycobacterial activity and reasonable safety that merits further research.
INTRODUCTION:Tuberculosis (TB) is one of the leading causes of morbidity and mortality with a global mortality rate at two million deaths per year while one third of the world's population is infected with the TB bacillus. OBJECTIVE: To determine the efficacy of the crude extracts of Erythrina abyssinica root bark on rifampicin-resistant TB. METHODS: Crude extracts of root bark of Erythrina abyssinica, were screened against three strains of Mycobacterium tuberculosis including rifampicin-resistant TMC-331. Susceptibility tests used the disc diffusion method and were done on solid Middle brook 7H10, while the Minimum Inhibitory concentration (MICs) and minimum bactericidal concentration (MBCs) were determined by the Microtitre plate method using Middle brook 7H9 broth. RESULTS: The total crude methanol extract showed activity against all the three strains of mycobacterium used, at 50mg/ml and diameters of zones of inhibition of up to 26 mm. Erythrina abyssinica total crude methanol extract showed the highest activity on the pan sensitive strain H37Rv (0.39±0.0 mg/ml) and the rifampicin resistant strain (TMC-331) (2.35±1.11 mg/ ml) and was also active on Mycobacterium avium (0.39±0.mg/ml. The values for isoniazid were 0.25µg/ml and 9.38µg/ml for H37Rv and TMC-331 respectively, while for rifampicin the MIC value was 0.25µg/ml for H37Rv but it was not active on TMC-331. Acute toxicity test gave an LD50 of 776.2mg/kg body weight while the phytochemical analysis showed the presence of alkaloids, tannins and flavones. CONCLUSION: The conclusion from the study was that Erythrina abbyssinica has antimycobacterial activity and reasonable safety that merits further research.
Authors: Guido F Pauli; Ryan J Case; Taichi Inui; Yuehong Wang; Sanghyun Cho; Nikolaus H Fischer; Scott G Franzblau Journal: Life Sci Date: 2005-10-21 Impact factor: 5.037
Authors: Matteo Zignol; Mehran S Hosseini; Abigail Wright; Catharina Lambregts-van Weezenbeek; Paul Nunn; Catherine J Watt; Brian G Williams; Christopher Dye Journal: J Infect Dis Date: 2006-07-12 Impact factor: 5.226
Authors: C A Peloquin; A T Nitta; W J Burman; K F Brudney; J R Miranda-Massari; M E McGuinness; S E Berning; G T Gerena Journal: Ann Pharmacother Date: 1996-09 Impact factor: 3.154
Authors: Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye Journal: Arch Intern Med Date: 2003-05-12
Authors: Samuel Baker Obakiro; Ambrose Kiprop; Isaac Kowino; Elizabeth Kigondu; Mark Peter Odero; Timothy Omara; Lydia Bunalema Journal: Trop Med Health Date: 2020-08-14
Authors: G Anywar; E Kakudidi; R Byamukama; J Mukonzo; A Schubert; H Oryem-Origa; C Jassoy Journal: Front Pharmacol Date: 2021-04-15 Impact factor: 5.810
Authors: Samuel Baker Obakiro; Ambrose Kiprop; Elizabeth Kigondu; Isaac K'Owino; Mark Peter Odero; Scolastica Manyim; Timothy Omara; Jane Namukobe; Richard Oriko Owor; Yahaya Gavamukulya; Lydia Bunalema Journal: Evid Based Complement Alternat Med Date: 2021-03-03 Impact factor: 2.629